Page last updated: 2024-09-03

n,n-dimethylarginine and pravastatin

n,n-dimethylarginine has been researched along with pravastatin in 5 studies

Compound Research Comparison

Studies (n,n-dimethylarginine)	Trials (n,n-dimethylarginine)	Recent Studies (post-2010) (n,n-dimethylarginine)	Studies (pravastatin)	Trials (pravastatin)	Recent Studies (post-2010) (pravastatin)
2,216	228	1,221	3,575	1,036	816

Protein Interaction Comparison

Protein	Taxonomy	pravastatin (IC50)
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Homo sapiens (human)	0.1452
Insulin receptor	Rattus norvegicus (Norway rat)	0.0056
Prostaglandin G/H synthase 2	Homo sapiens (human)	0.0056
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Rattus norvegicus (Norway rat)	0.0254
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	3.6

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arnesen, H; Eid, HM; Eritsland, J; Larsen, J; Seljeflot, I	1
Janatuinen, T; Knuuti, J; Laakso, J; Laaksonen, R; Lehtimäki, T; Nuutila, P; Raitakari, OT; Vesalainen, R	1
Kiefte-de Jong, JC; Nanayakkara, PW; Olthof, MR; Smulders, YM; Stehouwer, CD; Teerlink, T; ter Wee, PM; Twisk, JW; van Guldener, C; van Ittersum, FJ	1
Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M	1
Ishibashi, Y; Matsui, T; Nakamura, K; Ohta, K; Okuda, S; Takeuchi, M; Tanoue, R; Ueda, S; Yamagishi, S	1

Trials

4 trial(s) available for n,n-dimethylarginine and pravastatin

Article	Year
Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis, 2003, Volume: 166, Issue:2 Topics: Arginine; Arteriosclerosis; Cholesterol, LDL; Diabetes Mellitus, Type 1; Female; Humans; Hypercholesterolemia; Incidence; Male; Pravastatin; Predictive Value of Tests; Probability; Reference Values; Risk Assessment; Sensitivity and Specificity	2003
Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vascular medicine (London, England), 2003, Volume: 8, Issue:3 Topics: Adenosine; Adult; Anticholesteremic Agents; Arginine; Blood Flow Velocity; Coronary Circulation; Double-Blind Method; Enzyme Inhibitors; Humans; Hyperemia; Male; Nitric Oxide Synthase; Pravastatin; Regional Blood Flow; Tomography, Emission-Computed	2003
Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Arginine; Carotid Arteries; Chronic Disease; Creatinine; Double-Blind Method; Female; Folic Acid; Homocysteine; Humans; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Vitamin B 12; Vitamin B 6; Vitamin E	2009
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients. Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:2 Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke	2011

Other Studies

1 other study(ies) available for n,n-dimethylarginine and pravastatin

Article	Year
Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism: clinical and experimental, 2012, Volume: 61, Issue:8 Topics: Amidohydrolases; Apoptosis; Arginine; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Fluorobenzenes; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules, Proximal; Pravastatin; Pyrimidines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Up-Regulation	2012

Article

Year

Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level.

Metabolism: clinical and experimental, 2012, Volume: 61, Issue:8

Topics: Amidohydrolases; Apoptosis; Arginine; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Fluorobenzenes; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules, Proximal; Pravastatin; Pyrimidines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Up-Regulation

2012